Genentech's Rise Prompts Insiders To Sell Holdings
Article Abstract:
Genentech Inc., which is a leading biotechnology company, has reported rising stock price. Several of Genentech's top executives have sold as much as 30% of the biotech's stock or options as they sought to profit from the company's rising value, with one executive gaining over $10 million.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
Genentech reports rises in net income, revenue for quarter
Article Abstract:
Genentech Inc. posted a strong increase in its net income and revenue before charges for the 2001 second-quarter. The company posted $38.6 million in quarterly net income, compared to a $12.9 million net loss during the same 2000 period.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
Biogen net rises 2% on drug sales
Article Abstract:
Biogen posted an increase of 2% in its net income for the 2001 third-quarter. The company posted $69.8 million in net income for the period.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Maclean's rethinks its positioning. Sleeman tries CanWest bundle. Black and bleue
- Abstracts: Volvo's results fail to hit expectations. Investor's net rose 86% in first quarter. Volvo's profit declines, but beats tempered views
- Abstracts: Doubts on Internet alliance. China Everbright Holdings prepares for buying spree
- Abstracts: Television's final frontier. Soap opera. Another twist in the tale
- Abstracts: EMI confirms talks with Bertelsmann. GE's Welch intends to retire with Honeywell merger dead. GE names Gary Rogers its third vice chairman